Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Magnitude of CD8 T-cell responses against hepatitis C virus and severity of hepatitis do not necessarily determine outcomes in acute hepatitis C virus infection.
Doi H, Hiroishi K, Shimazaki T, Eguchi J, Baba T, Ito T, Matsumura T, Nozawa H, Morikawa K, Ishii S, Hiraide A, Sakaki M, Imawari M. Doi H, et al. Among authors: morikawa k. Hepatol Res. 2009 Mar;39(3):256-65. doi: 10.1111/j.1872-034X.2008.00459.x. Epub 2008 Nov 5. Hepatol Res. 2009. PMID: 19054151
Lymphotropic hepatitis C virus has an interferon-resistant phenotype.
Inokuchi M, Ito T, Nozawa H, Miyashita M, Morikawa K, Uchikoshi M, Shimozuma Y, Arai J, Shimazaki T, Hiroishi K, Imawari M. Inokuchi M, et al. Among authors: morikawa k. J Viral Hepat. 2012 Apr;19(4):254-62. doi: 10.1111/j.1365-2893.2011.01541.x. Epub 2011 Oct 17. J Viral Hepat. 2012. PMID: 22404723
Increased expression of immuno-inhibitory molecules on peripheral blood lymphocytes may suppress disease progression in autoimmune hepatitis.
Hiraide-Sasagawa A, Hiroishi K, Shimazaki T, Eguchi J, Ishii S, Morikawa K, Sakaki M, Doi H, Omori R, Kajiwara A, Hayashi E, Shiina M, Hirayama Y, Imawari M. Hiraide-Sasagawa A, et al. Among authors: morikawa k. Hepatol Res. 2015 Nov;45(11):1152-4. doi: 10.1111/hepr.12479. Hepatol Res. 2015. PMID: 25581267 No abstract available.
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T, Suda G, Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N. Kitagataya T, et al. Among authors: morikawa k. J Gastroenterol Hepatol. 2020 Oct;35(10):1782-1788. doi: 10.1111/jgh.15041. Epub 2020 Mar 31. J Gastroenterol Hepatol. 2020. PMID: 32187734 Free article.
Durable response without recurrence to Tolvaptan improves long-term survival.
Nakai M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Ohara M, Umemura M, Sho T, Morikawa K, Ogawa K, Sakamoto N. Nakai M, et al. Among authors: morikawa k. J Gastroenterol. 2020 Dec;55(12):1150-1161. doi: 10.1007/s00535-020-01721-8. Epub 2020 Aug 26. J Gastroenterol. 2020. PMID: 32851487
Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
Tsunematsu S, Suda G, Yamasaki K, Kimura M, Takaaki I, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N. Tsunematsu S, et al. Among authors: morikawa k. Hepatol Res. 2017 May;47(6):533-541. doi: 10.1111/hepr.12775. Epub 2016 Aug 11. Hepatol Res. 2017. PMID: 27423140
1,028 results